Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD.

J Natl Cancer Inst. 2010 May 5;102(9):627-37. doi: 10.1093/jnci/djq101. Epub 2010 Apr 28. Erratum in: J Natl Cancer Inst. 2010 Jul 7;102(13):993.

2.

HER2 as a prognostic factor in breast cancer.

Ménard S, Fortis S, Castiglioni F, Agresti R, Balsari A.

Oncology. 2001;61 Suppl 2:67-72. Review.

PMID:
11694790
3.
4.

In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer.

Kurbel S.

Tumour Biol. 2013 Feb;34(1):1-7. doi: 10.1007/s13277-012-0602-1. Epub 2012 Dec 4. Review.

PMID:
23208673
5.

Ductal carcinoma in situ: a disease entity that merits more recognition.

Dereere E, Papadimitriou K, Tjalma W, Altintas S.

Minerva Chir. 2015 Aug;70(4):231-9. Epub 2015 Apr 28. Review.

PMID:
25916193
6.

Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ.

Shamliyan T, Wang SY, Virnig BA, Tuttle TM, Kane RL.

J Natl Cancer Inst Monogr. 2010;2010(41):121-9. doi: 10.1093/jncimonographs/lgq034. Review.

7.

Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics.

Schnitt SJ.

J Natl Cancer Inst Monogr. 2010;2010(41):158-61. doi: 10.1093/jncimonographs/lgq031. Review.

8.

Mode of detection and secular time for ductal carcinoma in situ.

Pisano ED.

J Natl Cancer Inst Monogr. 2010;2010(41):142-4. doi: 10.1093/jncimonographs/lgq028. Review.

9.

Epidemiology of ductal carcinoma in situ.

Kerlikowske K.

J Natl Cancer Inst Monogr. 2010;2010(41):139-41. doi: 10.1093/jncimonographs/lgq027. Review.

10.

Molecular markers for the diagnosis and management of ductal carcinoma in situ.

Polyak K.

J Natl Cancer Inst Monogr. 2010;2010(41):210-3. doi: 10.1093/jncimonographs/lgq019. Review.

11.
12.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF; American Society of Clinical Oncology..

J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200/JCO.2015.65.2289. Epub 2016 Feb 8. Review.

13.

Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma.

Ernster VL, Barclay J.

J Natl Cancer Inst Monogr. 1997;(22):151-6. Review.

PMID:
9709292
14.

Ductal carcinoma in situ: risk factors and impact of screening.

Virnig BA, Wang SY, Shamilyan T, Kane RL, Tuttle TM.

J Natl Cancer Inst Monogr. 2010;2010(41):113-6. doi: 10.1093/jncimonographs/lgq024. Review.

15.

When is good enough really good enough? Defining the role of radiation in low-risk ductal carcinoma in situ.

Smith BD.

J Clin Oncol. 2015 Mar 1;33(7):686-91. doi: 10.1200/JCO.2014.59.4259. Epub 2015 Jan 20. Review. No abstract available.

PMID:
25605858
16.

NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry.

Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC.

J Natl Compr Canc Netw. 2009 Sep;7 Suppl 6:S1-S21; quiz S22-3. Review.

PMID:
19755043
17.

Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).

Groen EJ, Elshof LE, Visser LL, Rutgers EJ, Winter-Warnars HA, Lips EH, Wesseling J.

Breast. 2017 Feb;31:274-283. doi: 10.1016/j.breast.2016.09.001. Epub 2016 Sep 23. Review.

18.

The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer.

Brennan M, Lim B.

Adv Exp Med Biol. 2015;867:327-37. doi: 10.1007/978-94-017-7215-0_20. Review.

PMID:
26530375
19.

[Male breast cancer: history, epidemiology, genetic and histopathology].

Leinung S, Horn LC, Backe J.

Zentralbl Chir. 2007 Oct;132(5):379-85. Review. German.

PMID:
17907078
20.

Ductal carcinoma in situ - update on risk assessment and management.

Pang JM, Gorringe KL, Fox SB.

Histopathology. 2016 Jan;68(1):96-109. doi: 10.1111/his.12796. Review.

PMID:
26768032

Supplemental Content

Support Center